TCR2 Therapeutics (TCRR) Short Interest Ratio & Short Volume

Short interest is the volume of TCR2 Therapeutics shares that have been sold short but have not yet been closed out or covered. As of May 15th, investors have sold 360,900 shares of TCRR short. 1.15% of TCR2 Therapeutics' shares are currently sold short. Learn More on TCR2 Therapeutics' current short interest.

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. TCRR shares currently have a short interest ratio of 1.0. Learn More on TCR2 Therapeutics's short interest ratio.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 1.15% of TCR2 Therapeutics' floating shares are currently sold short.

TCR2 Therapeutics saw a drop in short interest in the month of May. As of May 15th, there was short interest totaling 360,900 shares, a drop of 15.9% from the previous total of 429,100 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

TCR2 Therapeutics currently has issued a total of 39,260,000 shares. Some of TCR2 Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. TCR2 Therapeutics currently has a public float of 31,340,000 shares.

1.15% of TCR2 Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "biological products, except diagnostic" compare to TCR2 Therapeutics: ProKidney Corp. (14.50%), Genfit S.A. (0.13%), Ocugen, Inc. (24.63%), SOPHiA GENETICS SA (0.09%), CARGO Therapeutics, Inc. (18.87%), Humacyte, Inc. (20.75%), Tevogen Bio Holdings Inc. (5.43%), Voyager Therapeutics, Inc. (5.75%), Innate Pharma S.A. (0.68%), enGene Holdings Inc. (0.30%),

As of the most recent reporting period, the following stocks had the largest short interest positions: Enbridge Inc. ($4.29 billion), T-Mobile US, Inc. ($4.17 billion), Charter Communications, Inc. ($3.07 billion), Occidental Petroleum Co. ($2.81 billion), Moderna, Inc. ($2.37 billion), Coinbase Global, Inc. ($2.27 billion), T. Rowe Price Group, Inc. ($1.98 billion), Verisk Analytics, Inc. ($1.94 billion), Extra Space Storage Inc. ($1.88 billion), and Xylem Inc. ($1.61 billion). View all of the most shorted stocks.

Short selling TCRR is an investing strategy that aims to generate trading profit from TCR2 Therapeutics as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for TCR2 Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of TCRR, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including TCRR, twice per month. The most recent reporting period available is May, 15 2023.